Hydroxyurea in Veterinary Oncology: Myeloproliferative-Disease Profile

hydroxyurea is covered as ribonucleotide-reductase inhibitors; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Ribonucleotide-reductase inhibitors; hazardous antineoplastic medicine. Hydroxyurea.

Hydroxyurea.

Hydroxyurea inhibits ribonucleotide reductase, reducing deoxyribonucleotide availability and DNA synthesis.

Merck lists polycythaemia vera, granulocytic and basophilic leukaemia, essential thrombocythaemia and investigational meningioma use. These uncommon diseases require a specific diagnosis; abnormal blood counts alone are not an indication.

Merck lists polycythaemia vera, granulocytic and basophilic leukaemia, essential thrombocythaemia and investigational meningioma use. These uncommon diseases require a specific diagnosis; abnormal blood counts alone are not an indication.

Oral hazardous medicine dispensed under a veterinary protocol

Veterinary evidence is disease-specific and often based on small cohorts or clinical experience. Investigational CNS use must be labelled as such and must not be equated with established tumour control.

Marrow suppression, nausea, vomiting, alopecia, claw sloughing, dysuria and possible liver toxicity are recognised. Capsules are hazardous and should not be opened or altered by caregivers unless the dispensing team has provided a validated method.

Other marrow suppressants and radiation can increase cytopenia risk. Breeding, pregnancy, household exposure and disposal require hazardous-drug review.

No FDA-approved canine or feline oncology indication was established for this medicine in this audit. In the United States, veterinary oncology use of an approved human or animal formulation is extra-label and must occur under a veterinarian within AMDUCA conditions and a valid VCPR.

Multi-region specialist use; product availability, extra-label prescribing law and pharmacy handling vary by jurisdiction.

Diagnosis-specific baseline testing, frequent blood counts during adjustment, organ-function review and clinical monitoring are central. Fever, bleeding, profound lethargy, urinary signs or painful claw changes require prompt veterinary contact.